Dépêches

Teleflex Reports Fourth Quarter and Full Year 2011 Results

Dépèche transmise le 23 février 2012 par Business Wire

Teleflex Reports Fourth Quarter and Full Year 2011 Results

Teleflex Reports Fourth Quarter and Full Year 2011 Results

LIMERICK, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) today announced financial results for the fourth quarter and full year ended December 31, 2011 as well as its preliminary outlook for 2012.

“As we look ahead, we are extremely optimistic about our growth prospects for 2012. Teleflex is well positioned as a medical device leader to capitalize on our growth opportunities and deliver superior shareholder value.”

THREE MONTH RESULTS

Fourth quarter 2011 net revenues were $411.7 million, an increase of 6.6% over the prior year period. Excluding the impact of foreign exchange, fourth quarter 2011 net revenues increased 6.8% over the prior year period.

Fourth quarter 2011 GAAP diluted earnings per share from continuing operations was $1.02, an increase of 209.1% over the prior year period. Fourth quarter 2011 adjusted diluted earnings per share from continuing operations was $1.07, an increase of 28.9% over the prior year period. Our profitability improvement, as compared to the fourth quarter of 2010, was related to an increase in sales volume, improved pricing, as well as a reduction in interest and income tax expenses. This was offset partially by higher manufacturing, raw material and fuel-related costs, continued investment in sales, marketing and research and development, and the recognition for adjusted earnings per share purposes of the cost associated with the early termination of an interest rate swap.

“Our solid fourth quarter performance capped off a very successful year for Teleflex,” said Benson Smith, Chairman, President and CEO. “Strong revenue growth was driven by our sales organization’s outstanding execution in all geographic regions, as well as improved customer service levels. Growth from all product categories and improved pricing trends in key markets contributed to the revenue gains. At the same time, we continued to make investments in sales and marketing, and research and development to support our longer-term growth objectives. We believe that during the course of 2011 we have created a platform that allows for sustainable and profitable growth in the future.”

Added Mr. Smith, “As we look ahead, we are extremely optimistic about our growth prospects for 2012. Teleflex is well positioned as a medical device leader to capitalize on our growth opportunities and deliver superior shareholder value.”

FOURTH QUARTER NET REVENUE BY PRODUCT GROUP

Critical Care fourth quarter 2011 net revenues were $268.2 million, an increase of 4.1% over the prior year period on an as reported basis. Excluding the impact of foreign exchange, fourth quarter 2011 net revenues increased 4.3% over the prior year period. The increase in revenue was due to higher sales of anesthesia, urology, respiratory and vascular access products.

Surgical Care fourth quarter 2011 net revenues were $73.5 million, an increase of 2.5% over the prior year period on an as reported basis. Excluding the impact of foreign exchange, fourth quarter 2011 net revenues increased 2.7% over the prior year period. The increase in revenue was due to higher sales of ligation products.

Cardiac Care fourth quarter 2011 net revenues were $22.0 million, an increase of 36.9% over the prior year period. Excluding the impact of foreign exchange, fourth quarter 2011 net revenues increased 37.7% over the prior year period. The increase in revenue was due to higher sales of intra-aortic balloon pumps and catheters, as well as the impact of a product recall which occurred in the prior year quarter.

OEM and Development Services fourth quarter 2011 net revenues were $47.7 million, an increase of 18.0% over the prior year period on an as reported basis. Excluding the impact of foreign exchange, fourth quarter 2011 net revenues increased 18.2% over the prior year period. The increase in revenue was due to higher sales of specialty suture and catheter fabrication products.

       
Three Months Ended % Increase/ (Decrease)

December 31,

2011

   

December 31,

2010

Constant

Currency

   

Foreign

Currency

   

Total

Change

(Dollars in millions)
Critical Care $ 268.2 $ 257.8 4.3 % (0.2 %) 4.1 %
Surgical Care 73.5 71.7 2.7 % (0.2 %) 2.5 %
Cardiac Care 22.0 16.1 37.7 % (0.8 %) 36.9 %
OEM 47.7 40.4 18.2 % (0.2 %) 18.0 %
Other   0.3   0.3      
Total $ 411.7 $ 386.3 6.8 % (0.2 %) 6.6 %
 

OTHER FINANCIAL INFORMATION AND PERFORMANCE METRICS

Depreciation and amortization expense of intangible assets and deferred financing costs and debt discount for the twelve months of 2011 was $99.1 million compared to $92.6 million for the prior year period.

Net cash provided by operating activities from continuing operations for the twelve months of 2011 was $103.1 million compared to $151.6 million for the prior year period.

Cash and cash equivalents at December 31, 2011 were $584.1 million.

Net accounts receivable at December 31, 2011 were $286.2 million.

Net inventories at December 31, 2011 were $298.8 million.

Net debt obligations at December 31, 2011 were $445.9 million.

The Company finds that comparisons to the December 31, 2010 balance sheet amounts are not meaningful because several businesses were sold during 2011.

TWELVE MONTH RESULTS

Net revenues for the twelve months of 2011 were $1.53 billion, an increase of 6.7% over the prior year period. Excluding the impact of foreign exchange, net revenues for the twelve months of 2011 increased 4.3% over the prior year period.

GAAP diluted earnings per share from continuing operations for the twelve months of 2011 was $2.96, an increase of 33.9% over the prior year period. Adjusted diluted earnings per share from continuing operations for the twelve months of 2011 was $3.93, an increase of 4.2% over the prior year period. The increase in adjusted diluted earnings per share is related to an increase in sales volume and reduced interest and income tax expenses. This was somewhat offset by higher manufacturing, raw material and fuel-related freight costs, unfavorable product mix, the continued investment in sales, marketing and research and development, and the acceleration of expense due to the early termination of an interest rate swap.

2012 OUTLOOK

The Company’s financial estimates for 2012 are as follows:

Constant currency revenue growth between 4.0% and 6.0% for full year 2012.

Adjusted earnings per share in the range of $4.25 to $4.45.

           

2012 OUTLOOK EARNINGS PER SHARE RECONCILIATION

 
Low       High
 
Diluted earnings per share attributable to common shareholders $3.18 $3.38
 
Special items, net of tax $0.25 $0.25
 
Intangible amortization expense, net of tax $0.66 $0.66
 
Amortization of debt discount on convertible notes, net of tax $0.16       $0.16
 
Adjusted earnings per share $4.25       $4.45
 

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

As previously announced, Teleflex will comment on its financial results on a conference call to be held today at 8:00 a.m. (ET). The call will be available live and archived on the company’s website at www.teleflex.com and the accompanying presentation will be posted prior to the call. An audio replay will be available until February 28, 2012, 12:00pm (ET), by calling 888-286-8010 (U.S./Canada) or 617-801-6888 (International), Passcode: 36708812.

ADDITIONAL NOTES

Constant currency revenue and growth exclude the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. Constant currency revenue and growth include activity of a purchased company beyond the initial twelve months after the date of acquisition.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Product group results and commentary exclude the impact of discontinued operations, items included in restructuring and impairment charges, and losses and other charges set forth in the condensed consolidated statements of income.

NOTES ON NON-GAAP FINANCIAL MEASURES

This press release includes certain non-GAAP financial measures. These measures include (i) adjusted diluted earnings per share, which excludes the effect of charges associated with our restructuring programs and asset impairments, losses and other charges related to refinancing transactions, costs associated with severance payments and benefits to be provided to our former chief executive officer, charges related to product rationalizations, intangible amortization expense and the amortization of debt discount on convertible notes; and (ii) constant currency revenue and growth, which exclude the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. Consistent with past practice, adjusted diluted earnings per share has not been adjusted to exclude the benefit resulting from the forfeiture of equity awards. Management believes these measures are useful to investors because they eliminate items that do not reflect Teleflex’s day-to-day operations. In addition, management uses these financial measures for internal managerial purposes, when publicly providing guidance on possible future results, and to assist in our evaluation of period-to-period comparisons. These financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Tables reconciling these non-GAAP measures to the most directly comparable GAAP measures are set forth below; provided, however, that a reconciliation of forecasted constant currency revenue growth has not been provided as management is unable to forecast trends in foreign currency exchange rates.

   

RECONCILIATION OF INCOME FROM CONTINUING OPERATIONS

 
Three Months Ended Three Months Ended
December 31, 2011 December 31, 2010

(Dollars in thousands, except per share)

Income and diluted earnings per share attributable to common

$

41,664

$

13,404

shareholders $1.02 $0.33
 
Intangible amortization expense 10,917 10,456
Tax benefit  

(4,051

)

 

(3,840

)

Intangible amortization expense, net of tax   6,866     6,616  
$0.17 $0.16
 
Amortization of debt discount on convertible notes 2,487 2,303
Tax benefit  

(909

)

 

(838

)

Amortization of debt discount on convertible notes, net of tax   1,578     1,465  
$0.04 $0.04
 
Restructuring and impairment charges 4,058 1,196
Tax benefit   (1,540 )   (360 )
Restructuring and impairment charges, net of tax   2,518     836  
$0.06 $0.02

 

Losses and other charges (A) 2,554 22,048
Tax benefit   (791 )   (8,126 )
Losses and other charges, net of tax   1,763     13,922  
$0.04 $0.35

 

Early termination of interest rate swap (B) (11,056 )
Tax expense   4,024      
Early termination of interest rate swap, net of tax

 

(7,032 )    
($0.17 )
 
Tax Adjustments (C)   (3,334 )   (2,939 )
($0.08 ) ($0.07 )
 
Adjusted income and diluted earnings per share

$

44,023

 

$

33,304

 
$1.07 $0.83
 

(A) In 2011, losses and other charges include costs attributed to a Stock Keeping Unit (“SKU”) rationalization to eliminate SKUs based on low sales volume or insufficient margins to help improve future profitability. The net of tax impact was approximately $1.3 million, or $0.03 per share; $0.4 million, net of tax, or $0.01 per share, related to the sale of a facility. In 2010, losses and other charges include approximately $10.4 million, net of tax, or $0.26 per share, related to the loss on extinguishment of debt; $3.6 million, net of tax, or $0.09 per share, related to factory shut-down costs associated with the custom IV tubing product.

(B) In 2011, the Company terminated an interest rate swap that, at the date of termination, had a notional amount of $350 million. The interest rate swap was designated as a cash flow hedge against the term loan under our senior credit facility. At the date of termination, the interest rate swap was in a liability position resulting in a cash payment of approximately $14.8 million, which included $3.1 million of accrued interest. The net of tax impact was approximately $7.0 million, or $0.17 per share. For GAAP purposes, the Company will amortize this amount as additional interest expense over the original term of the interest rate swap which was scheduled to expire in September 2012.

(C) The tax adjustment represents a net benefit resulting from the resolution (including the expiration of statutes of limitations) of various prior years’ U.S. federal, state and foreign tax matters.

   

RECONCILIATION OF INCOME FROM CONTINUING OPERATIONS

 
Twelve Months Ended Twelve Months Ended
December 31, 2011 December 31, 2010

(Dollars in thousands, except per share)

Income and diluted earnings per share attributable to common $ 120,682 $ 88,829
shareholders $2.96 $2.21
 
Intangible amortization expense 44,113 42,244
Tax benefit  

(16,168

)

 

(15,378 )
Intangible amortization expense, net of tax   27,945     26,866  
$0.68 $0.67
 
Amortization of debt discount on convertible notes 9,699 3,839
Tax benefit  

(3,530

)

 

(1,395 )
Amortization of debt discount on convertible notes, net of tax   6,169     2,444  
$0.15 $0.06
 
Restructuring and impairment charges 4,768 2,875
Tax benefit   (1,790 )   (1,012 )
Restructuring and impairment charges, net of tax   2,978     1,863  
$0.07 $0.05
 
Losses and other charges (A) 23,467 54,790
Tax benefit   (8,392 )   (19,992 )
Losses and other charges, net of tax   15,075     34,798  
$0.37 $0.86

 

Early termination of interest rate swap (B) (11,056 )
Tax expense   4,024      
Early termination of interest rate swap, net of tax   (7,032 )    
($0.17 )
 
Tax adjustments (C)   (5,499 )   (2,939 )
($0.13 ) ($0.07 )
 
Adjusted income and diluted earnings per share $ 160,318   $ 151,861  
$3.93 $3.77
 

(A) In 2011, losses and other charges include approximately $9.8 million, net of tax, or $0.24 per share, related to the loss on extinguishment of debt; approximately $3.5 million, net of tax, or $0.09 per share, in charges related to severance payments and benefits to be provided to our former chief executive officer; costs attributed to a Stock Keeping Unit (“SKU”) rationalization to eliminate SKUs based on low sales volume or insufficient margins to help improve future profitability. The net of tax impact was approximately $1.3 million, or $0.03 per share; and approximately $0.4 million, net of tax, or $0.01 per share, related to the sale of a facility. In 2010, losses and other charges include approximately $31.3 million, net of tax, or $0.78 per share, related to the loss on extinguishment of debt; and approximately $3.6 million, net of tax, or $0.09 per share, related to factory shut-down costs associated with the custom IV tubing product.

(B) In 2011, the Company terminated an interest rate swap that, at the date of termination, had a notional amount of $350 million. The interest rate swap was designated as a cash flow hedge against the term loan under our senior credit facility. At the date of termination, the interest rate swap was in a liability position resulting in a cash payment of approximately $14.8 million, which included $3.1 million of accrued interest. The net of tax impact was approximately $7.0 million, or $0.17 per share. For GAAP purposes, the Company will amortize this amount as additional interest expense over the original term of the interest rate swap which was scheduled to expire in September 2012.

(C) The tax adjustment represents a net benefit resulting from the resolution (including the expiration of statutes of limitations) of various prior years’ U.S. federal, state and foreign tax matters.

   

RECONCILIATION OF NET DEBT OBLIGATIONS

 
December 31, 2011 December 31, 2010
(Dollars in thousands)
Note payable and current portion of long-term borrowings $ 4,986 $ 103,711
 
Long term borrowings 954,809 813,409
 
Unamortized debt discount   70,191   79,891
 
Total debt obligations 1,029,986 997,011
 
Less: cash and cash equivalents   584,088   208,452
 
Net debt obligations $ 445,898 $ 788,559
 

ABOUT TELEFLEX INCORPORATED

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,500 people worldwide and serves healthcare providers in more than 130 countries. For additional information about Teleflex please refer to www.teleflex.com.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, statements relating to forecasted 2012 constant currency revenue growth and adjusted earnings per share. Actual results could differ materially from those in the forward-looking statements due to, among other things, conditions in the end markets we serve, customer reaction to new products and programs, our ability to achieve sales growth, price increases or cost reductions; changes in the reimbursement practices of third party payors; our ability to realize efficiencies and to execute on our strategic initiatives; changes in material costs and surcharges; market acceptance and unanticipated difficulties in connection with the introduction of new products and product line extensions; product recalls; unanticipated difficulties in connection with the consolidation of manufacturing and administrative functions; unanticipated difficulties, expenditures and delays in complying with government regulations applicable to our businesses; the impact of government healthcare reform legislation; our ability to meet our debt obligations; changes in general and international economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

 
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
 
Three Months Ended
December 31,   December 31,
2011 2010
(Dollars and shares in thousands,

except per share)

 
Net revenues $ 411,730 $ 386,277
Cost of goods sold   219,699     209,482  
Gross profit 192,031 176,795
Selling, general and administrative expenses 111,924 112,963
Research and development expenses 12,913 12,451
Restructuring and other impairment charges 3,494 1,196
Net loss (gain) on sales of businesses and assets   582     (158 )
Income from continuing operations before interest, loss on extinguishments of debt and taxes 63,118 50,343
Interest expense 19,209 21,288
Interest income (584 ) (144 )
Loss on extinguishments of debt       16,276  
Income from continuing operations before taxes 44,493 12,923
Taxes (benefit) on income from continuing operations   2,578     (685 )
Income from continuing operations   41,915     13,608  
Operating income from discontinued operations (including gain on disposal of $218,365 and $76,140, respectively) 216,932 91,575
Taxes on income from discontinued operations   90,626     23,747  
Income from discontinued operations   126,306     67,828  
Net income 168,221 81,436
Less: Income from continuin

Business Wire

Les plus belles photos d'avions
Boeing 737-36Q/WL (YL-BBX) Sukhoi Superjet 100-95B (RA-89028) Cessna 525 CitationJet CJ1 (SE-RGX) Bombardier CSeries CS300 (BD-500-1A11) (YL-CSC) PZL-Mielec M-28B1TD Bryza 1TD (1117) Boeing 737-522 (YL-BBN)